Patents by Inventor Xue-Ping Wang

Xue-Ping Wang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • HUMANIZED MONOCLONAL ANTIBODIES AND METHODS OF USE FOR THE DIAGNOSIS AND TREATMENT OF COLON AND PANCREAS CANCER
    Publication number: 20230295298
    Abstract: This invention relates to humanized antibodies that selectively bind the 31.1 epitope on the A33 protein differentially expressed in cancers including, lung cancer, ovarian cancer, pancreas cancer, breast cancer, and colon cancer, and diagnostic and therapeutic usages.
    Type: Application
    Filed: October 20, 2022
    Publication date: September 21, 2023
    Inventors: Xue-Ping Wang, Philip M. Arlen
  • COLON AND PANCREAS CANCER SPECIFIC ANTIGENS AND ANTIBODIES
    Publication number: 20230032624
    Abstract: This invention relates to NPC-1 antigen on the MUC5AC protein and 16C3 antigen on CEACAM5 and CEACAM6 proteins, and 31.1 epitope on the A33 protein are differentially expressed in cancers including, lung cancer, ovarian cancer, pancreas cancer, breast cancer, and colon cancer, and diagnostic and therapeutic usages. Further, NPC-1, 16C3, and/or 31.1 epitope specific antibodies and diagnostic and therapeutic methods of use.
    Type: Application
    Filed: May 9, 2022
    Publication date: February 2, 2023
    Inventors: Xiulian DU, Janos LUKA, Lewis Joe STAFFORD, Mark Semenuk, Xue-Ping WANG, Judith KANTOR, Andrew BRISTOL
  • Humanized monoclonal antibodies and methods of use for the diagnosis and treatment of colon and pancreas cancer
    Patent number: 11505604
    Abstract: This invention relates to humanized antibodies that selectively bind the 31.1 epitope on the A33 protein differentially expressed in cancers including, lung cancer, ovarian cancer, pancreas cancer, breast cancer, and colon cancer, and diagnostic and therapeutic usages.
    Type: Grant
    Filed: May 15, 2020
    Date of Patent: November 22, 2022
    Assignee: PRECISION BIOLOGICS, INC.
    Inventors: Xue-Ping Wang, Philip M. Arlen
  • Colon and pancreas cancer specific antigens and antibodies
    Patent number: 11345733
    Abstract: This invention relates to NPC-1 antigen on the MUC5AC protein and 16C3 antigen on CEACAM5 and CEACAM6 proteins, and 31.1 epitope on the A33 protein are differentially expressed in cancers including, lung cancer, ovarian cancer, pancreas cancer, breast cancer, and colon cancer, and diagnostic and therapeutic usages. Further, NPC-1, 16C3, and/or 31.1 epitope specific antibodies and diagnostic and therapeutic methods of use.
    Type: Grant
    Filed: November 30, 2018
    Date of Patent: May 31, 2022
    Assignee: PRECISION BIOLOGICS, INC.
    Inventors: Xiulian Du, Janos Luka, Lewis Joe Stafford, Mark Semenuk, Xue-Ping Wang, Judith Kantor, Andrew Bristol
  • Colon and Pancreas Cancer Peptidomimetics
    Publication number: 20210395321
    Abstract: The invention relates to a peptidomimetic of an NPC-1 epitope on the MUC5AC protein which is differentially expressed in pancreatic and colorectal cancer, and diagnostic and therapeutic usages. Further, antibodies that selectively bind the NPC-1 epitope peptidomimetics and may be used in diagnostic and therapeutic methods.
    Type: Application
    Filed: June 24, 2021
    Publication date: December 23, 2021
    Inventor: Xue-Ping WANG
  • Colon and pancreas cancer peptidomimetics
    Patent number: 11078245
    Abstract: The invention relates to a peptidomimetic of an NPC-1 epitope on the MUC5AC protein which is differentially expressed in pancreatic and colorectal cancer, and diagnostic and therapeutic usages. Further, antibodies that selectively bind the NPC-1 epitope peptidomimetics and may be used in diagnostic and therapeutic methods.
    Type: Grant
    Filed: November 27, 2019
    Date of Patent: August 3, 2021
    Assignee: PRECISION BIOLOGICS, INC.
    Inventor: Xue-Ping Wang
  • HUMANIZED MONOCLONAL ANTIBODIES AND METHODS OF USE FOR THE DIAGNOSIS AND TREATMENT OF COLON AND PANCREAS CANCER
    Publication number: 20210002368
    Abstract: This invention relates to humanized antibodies that selectively bind the 31.1 epitope on the A33 protein differentially expressed in cancers including, lung cancer, ovarian cancer, pancreas cancer, breast cancer, and colon cancer, and diagnostic and therapeutic usages.
    Type: Application
    Filed: May 15, 2020
    Publication date: January 7, 2021
    Inventors: Xue-Ping WANG, Philip M. ARLEN
  • Humanized monoclonal antibodies and methods of use for the diagnosis and treatment of colon and pancreas cancer
    Patent number: 10689443
    Abstract: This invention relates to humanized antibodies that selectively bind the 31.1 epitope on the A33 protein differentially expressed in cancers including, lung cancer, ovarian cancer, pancreas cancer, breast cancer, and colon cancer, and diagnostic and therapeutic usages.
    Type: Grant
    Filed: March 23, 2018
    Date of Patent: June 23, 2020
    Assignee: PRECISION BIOLOGICS, INC.
    Inventors: Xue-Ping Wang, Philip M. Arlen
  • Colon and Pancreas Cancer Peptidomimetics
    Publication number: 20200165310
    Abstract: The invention relates to a peptidomimetic of an NPC-1 epitope on the MUC5AC protein which is differentially expressed in pancreatic and colorectal cancer, and diagnostic and therapeutic usages. Further, antibodies that selectively bind the NPC-1 epitope peptidomimetics and may be used in diagnostic and therapeutic methods.
    Type: Application
    Filed: November 27, 2019
    Publication date: May 28, 2020
    Inventor: Xue-Ping WANG
  • Colon and pancreas cancer peptidomimetics
    Patent number: 10533040
    Abstract: The invention relates to a peptidomimetic of an NPC-1 epitope on the MUC5AC protein which is differentially expressed in pancreatic and colorectal cancer, and diagnostic and therapeutic usages. Further, antibodies that selectively bind the NPC-1 epitope peptidomimetics and may be used in diagnostic and therapeutic methods.
    Type: Grant
    Filed: June 26, 2017
    Date of Patent: January 14, 2020
    Assignee: PRECISION BIOLOGICS, INC.
    Inventor: Xue-Ping Wang
  • COLON AND PANCREAS CANCER SPECIFIC ANTIGENS AND ANTIBODIES
    Publication number: 20190322720
    Abstract: This invention relates to NPC-1 antigen on the MUC5AC protein and 16C3 antigen on CEACAM5 and CEACAM6 proteins, and 31.1 epitope on the A33 protein are differentially expressed in cancers including, lung cancer, ovarian cancer, pancreas cancer, breast cancer, and colon cancer, and diagnostic and therapeutic usages. Further, NPC-1, 16C3, and/or 31.1 epitope specific antibodies and diagnostic and therapeutic methods of use.
    Type: Application
    Filed: November 30, 2018
    Publication date: October 24, 2019
    Inventors: Xiulian DU, Janos LUKA, Lewis Joe STAFFORD, Mark Semenuk, Xue-Ping WANG, Judith KANTOR, Andrew BRISTOL
  • HUMANIZED MONOCLONAL ANTIBODIES AND METHODS OF USE FOR THE DIAGNOSIS AND TREATMENT OF COLON AND PANCREAS CANCER
    Publication number: 20180265583
    Abstract: This invention relates to humanized antibodies that selectively bind the 31.1 epitope on the A33 protein differentially expressed in cancers including, lung cancer, ovarian cancer, pancreas cancer, breast cancer, and colon cancer, and diagnostic and therapeutic usages.
    Type: Application
    Filed: March 23, 2018
    Publication date: September 20, 2018
    Inventors: Xue-Ping WANG, Philip M. ARLEN
  • Humanized monoclonal antibodies and methods of use for the diagnosis and treatment of colon and pancreas cancer
    Patent number: 9938344
    Abstract: This invention relates to humanized antibodies that selectively bind the 31.1 epitope on the A33 protein differentially expressed in cancers including, lung cancer, ovarian cancer, pancreas cancer, breast cancer, and colon cancer, and diagnostic and therapeutic usages.
    Type: Grant
    Filed: December 30, 2013
    Date of Patent: April 10, 2018
    Assignee: PRECISION BIOLOGICS, INC.
    Inventors: Xue-Ping Wang, Philip M. Arlen
  • COLON AND PANCREAS CANCER PEPTIDOMIMETICS
    Publication number: 20170362288
    Abstract: The invention relates to a peptidomimetic of an NPC-1 epitope on the MUC5AC protein which is differentially expressed in pancreatic and colorectal cancer, and diagnostic and therapeutic usages. Further, antibodies that selectively bind the NPC-1 epitope peptidomimetics and may be used in diagnostic and therapeutic methods.
    Type: Application
    Filed: June 26, 2017
    Publication date: December 21, 2017
    Inventor: Xue-Ping WANG
  • Colon and pancreas cancer peptidomimetics
    Patent number: 9718866
    Abstract: The invention relates to a peptidomimetic of an NPC-1 epitope on the MUC5AC protein which is differentially expressed in pancreatic and colorectal cancer, and diagnostic and therapeutic usages. Further, antibodies that selectively bind the NPC-1 epitope peptidomimetics and may be used in diagnostic and therapeutic methods.
    Type: Grant
    Filed: May 29, 2015
    Date of Patent: August 1, 2017
    Assignee: Precision Biologics, Inc.
    Inventor: Xue-Ping Wang
  • Humanized Monoclonal Antibodies and Methods of Use for the Diagnosis and Treatment of Colon and Pancreas Cancer
    Publication number: 20160194398
    Abstract: This invention relates to humanized antibodies that selectively bind the 31.1 epitope on the A33 protein differentially expressed in cancers including, lung cancer, ovarian cancer, pancreas cancer, breast cancer, and colon cancer, and diagnostic and therapeutic usages.
    Type: Application
    Filed: December 30, 2013
    Publication date: July 7, 2016
    Inventors: Xue-Ping WANG, Philip M. ARLEN
  • Colon and Pancreas Cancer Peptidomimetics
    Publication number: 20150337023
    Abstract: The invention relates to a peptidomimetic of an NPC-1 epitope on the MUC5AC protein which is differentially expressed in pancreatic and colorectal cancer, and diagnostic and therapeutic usages. Further, antibodies that selectively bind the NPC-1 epitope peptidomimetics and may be used in diagnostic and therapeutic methods.
    Type: Application
    Filed: May 29, 2015
    Publication date: November 26, 2015
    Inventor: Xue-Ping Wang
  • Colon and pancreas cancer peptidomimetics
    Patent number: 9068014
    Abstract: The invention relates to a peptidomimetic of an NPC-1 epitope on the MUC5AC protein which is differentially expressed in pancreatic and colorectal cancer, and diagnostic and therapeutic usages. Further, antibodies that selectively bind the NPC-1 epitope peptidomimetics and may be used in diagnostic and therapeutic methods.
    Type: Grant
    Filed: September 23, 2011
    Date of Patent: June 30, 2015
    Assignee: PRECISION BIOLOGICS, INC.
    Inventor: Xue-Ping Wang
  • COLON AND PANCREAS CANCER PEPTIDOMIMETICS
    Publication number: 20130247232
    Abstract: The invention relates to a peptidomimetic of an NPC-1 epitope on the MUC5AC protein which is differentially expressed in pancreatic and colorectal cancer, and diagnostic and therapeutic usages. Further, antibodies that selectively bind the NPC-1 epitope peptidomimetics and may be used in diagnostic and therapeutic methods.
    Type: Application
    Filed: September 23, 2011
    Publication date: September 19, 2013
    Applicant: NEOGENIX ONCOLOGY, INC.
    Inventor: Xue-Ping Wang
  • COLON AND PANCREAS CANCER SPECIFIC ANTIGENS AND ANTIBODIES
    Publication number: 20130189268
    Abstract: This invention relates to NPC-1 antigen on the MUC5AC protein and 16C3 antigen on CEACAM5 and CEACAM6 proteins, and 31.1 epitope on the A33 protein are differentially expressed in cancers including, lung cancer, ovarian cancer, pancreas cancer, breast cancer, and colon cancer, and diagnostic and therapeutic usages. Further, NPC-1, 16C3, and/or 31.1 epitope specific antibodies and diagnostic and therapeutic methods of use.
    Type: Application
    Filed: June 22, 2011
    Publication date: July 25, 2013
    Applicant: Precision Biologics, Inc.
    Inventors: Xiulian Du, Janos Luka, Lewis Joe Stafford, Mark Semenuk, Xue-Ping Wang, Judith Kantor, Andrew J. Bristol